Effective December 1, 2016, all new Special Authorization requests for the treatment of Moderately to Severely Active Crohn's Disease and Fistulizing Crohn's Disease or Ulcerative Colitis for infliximab naive patients will be assessed for coverage with Inflectra. Remicade will not be approved for new infliximab starts for patients with the ... Read More


Alberta Health amended their price policy on September 26, 2016 to come into effect on October 1, 2016. The following amendments were made: Amendment to the Maximum Allowable (MAC) Price Policy of the Alberta Price Policy Effective October 1, 2016, the MAC Price Policy, section 2-14, will be amended to include eligible ... Read More


The Alberta Price Confirmation (APC) is issued prior to an Alberta Drug Benefit List (ADBL) publication. The APC is a requirement for listing on the ADBL. The APC Tentative Issue Dates are subject to change.   ADBL Effective Date APC Tentative Issue Date March 1, 2016 February 2, 2016 April 1, 2016 February 18, ... Read More


Please be advised that updates to the Manufacturer Submission Policy were published effective April 1, 2015 and can be found at: https://idbl.ab.bluecross.ca/idbl/PDFS/dbl_sec1_drug.pdf Should Manufacturers require additional clarification regarding the published Manufacturer Submission Policy please contact Alberta Blue Cross, Scientific and Research Services at: submissions@ab.bluecross.ca For more information, please see ... Read More


Drug manufacturer submission deadlines for listing on the AHWDBL have been updated.


As part of the Alberta Government’s 2013-2014 budget announced last week, a new generic drug pricing rule is effective in the province beginning today. Formerly priced at about 35 percent of the brand price, generic drugs will be 18 percent of the corresponding brand drug price for public ... Read More